Academic Journal
Comparative effectiveness of COVID-19 vaccines among health students, focusing on methodological concerns.
| Τίτλος: | Comparative effectiveness of COVID-19 vaccines among health students, focusing on methodological concerns. |
|---|---|
| Συγγραφείς: | Cakir B; Hacettepe Universitesi Tip Fakultesi, Türkiye., Sertcelik A; Ankara Yıldırım Beyazıt Üniversitesi Tıp Fakültesi: Ankara Yildirim Beyazit Univ, Türkiye., Karadogan E; Ministry of Health, Türkiye, Antalya, Türkiye., Uzar H; Republic of Turkey Ministry of Health: Turkiye Cumhuriyeti Saglik Bakanligi, Türkiye., Temizer M; Manisa Celal Bayar University: Manisa Celal Bayar Universitesi, Türkiye., Kara SA; Republic of Turkey Ministry of Health: Turkiye Cumhuriyeti Saglik Bakanligi, Türkiye., Ozden ME; Republic of Turkey Ministry of Health: Turkiye Cumhuriyeti Saglik Bakanligi, Türkiye., Buzgan B; Hacettepe University: Hacettepe Universitesi, Türkiye., Ozyurek D; Bandirma Onyedi Eylul Universitesi, Türkiye., Alp A; Hacettepe Universitesi Tip Fakultesi, Türkiye., Pinar A; Hacettepe Universitesi Tip Fakultesi, Türkiye., Ayhan Baser D; Hacettepe Universitesi Tip Fakultesi, Türkiye., Aksoy H; Hacettepe Universitesi Tip Fakultesi, Türkiye., Fidanci I; Hacettepe Universitesi Tip Fakultesi, Türkiye., Calik Basaran N; Hacettepe Universitesi Tip Fakultesi, Türkiye., Ozyavuz Alp S; Hacettepe Universitesi Tip Fakultesi, Türkiye., Arslan V; Hacettepe Universitesi Tip Fakultesi, Türkiye., Sener B; Hacettepe Universitesi Tip Fakultesi, Türkiye. |
| Πηγή: | Antimicrobial stewardship & healthcare epidemiology : ASHE [Antimicrob Steward Healthc Epidemiol] 2026 Apr 07; Vol. 6 (1), pp. e91. Date of Electronic Publication: 2026 Apr 07 (Print Publication: 2026). |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Cambridge University Press Country of Publication: England NLM ID: 9918266096106676 Publication Model: eCollection Cited Medium: Internet ISSN: 2732-494X (Electronic) Linking ISSN: 2732494X NLM ISO Abbreviation: Antimicrob Steward Healthc Epidemiol Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: [Cambridge] : Cambridge University Press, [2021]- |
| Περίληψη: | Introduction: With emerging variants of SARS-CoV-2, there is an increasing demand for comprehensive data on vaccine effectiveness disaggregated by vaccine type and/or country to frame future pandemic readiness plans. Design Setting Participants: We investigated comparative effectiveness (VE) of CoronaVac® and Comirnaty® vaccines among health students, considering potential risk factors. An open, prospective cohort study was conducted to follow participants with valid COVID-19 vaccinations, up to 2 years. Investigations included VE against symptomatic PCR-confirmed COVID-19 infections, along with vaccine-induced humoral immunity (including durability) and potential methodologic threats to conclusive decisions. Results: Symptomatic COVID-19 incidence rate was 4.24 (95% CI = 3.69-4.86) per 10,000 person-days among 1133 students (46.6% males) over 478,466 person-days. Taking a primary series/booster with CoronaVac as the reference, a primary series with Comirnaty or a Comirnaty booster protected students up to twenty times early in the pandemic, adjusting for covariates; significance disappeared in the Omicron period, though. Unexpected upsurges in virus-specific antibody levels, starting 3-6 months after the last vaccination when titers decreased to almost nill, suggested that disproportionality in vaccine durability could have led to a bias towards the null in VE estimates, due to mediator role of undetected breakthrough infections. Conclusion: Hybrid immunity may differentially deplete the susceptibles in either arm of the study, leading to bias in VE estimations. High infection rate in Omicron period might have augmented this bias, favoring the protective effect of the less potent vaccine. Periodic PCR testing as an integrated measure in future VE studies can avoid such bias. (© The Author(s) 2026.) |
| Competing Interests: | The authors have no relevant financial or non-financial interest to disclose. |
| References: | Respirology. 2022 Apr;27(4):260-261. (PMID: 35229416) Front Immunol. 2021 Apr 12;12:669339. (PMID: 33912196) Euro Surveill. 2022 Jan;27(2):. (PMID: 35027105) Allergy. 2022 Aug;77(8):2459-2467. (PMID: 35437772) JMIR Res Protoc. 2026 Jan 27;15:e80858. (PMID: 41592795) Vaccine. 2022 Jul 30;40(32):4312-4317. (PMID: 35701327) Lancet. 2021 Jul 17;398(10296):213-222. (PMID: 34246358) Respirology. 2022 Apr;27(4):301-310. (PMID: 34820940) Cell Rep Med. 2022 Nov 15;3(11):100793. (PMID: 36257326) J Med Virol. 2022 May;94(5):2212-2221. (PMID: 35075655) Commun Med (Lond). 2021 Oct 13;1:38. (PMID: 35602204) BMJ. 2021 Jun 24;373:n1626. (PMID: 34168002) Work. 2023;74(3):799-809. (PMID: 36442185) Sci Transl Med. 2023 Feb 15;15(683):eade6023. (PMID: 36791210) Pak J Med Sci. 2024 Sep;40(8):1702-1708. (PMID: 39281253) Balkan Med J. 2023 Apr 28;40(3):215-221. (PMID: 37114621) Int J Infect Dis. 2024 Sep;146:107149. (PMID: 38909928) |
| Entry Date(s): | Date Created: 20260427 Date Completed: 20260427 Latest Revision: 20260813 |
| Update Code: | 20260920 |
| PubMed Central ID: | PMC13104580 |
| DOI: | 10.1017/ash.2026.10338 |
| PMID: | 42038640 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!